Insider Buying: Gain Therapeutics, Inc. (NASDAQ:GANX) Director Buys 17,000 Shares of Stock

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Eric I. Richman bought 17,000 shares of Gain Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was bought at an average cost of $1.22 per share, with a total value of $20,740.00. Following the completion of the purchase, the director now owns 289,629 shares in the company, valued at approximately $353,347.38. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Gain Therapeutics Price Performance

Shares of NASDAQ:GANX opened at $1.16 on Thursday. The company’s 50-day moving average price is $2.19 and its two-hundred day moving average price is $3.26. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.77 and a quick ratio of 2.77. Gain Therapeutics, Inc. has a one year low of $1.11 and a one year high of $5.33.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Research analysts anticipate that Gain Therapeutics, Inc. will post -1.11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on GANX shares. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a research note on Wednesday, March 27th. HC Wainwright cut their price target on shares of Gain Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Oppenheimer reissued an “outperform” rating and set a $9.00 price target on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.